Sign Up Today and Learn More About Abdera Therapeutics Stock
Invest in or calculate the value of your shares in Abdera Therapeutics or other pre-IPO companies through EquityZen's platform.
Abdera Therapeutics Stock (ABTH)
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
About Abdera Therapeutics Stock
Founded
2021
Industries
Science and Engineering, Health Care, Biotechnology
Abdera Therapeutics Press Mentions
Stay in the know about the latest news on Abdera Therapeutics
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
businesswire • Aug 03, 2024
Abdera’s DLL3-targeting radiopharmaceutical gets IND clearance
bioworld • Aug 03, 2024
FDA grants IND clearance for Abdera's Phase I cancer therapy trial
clinicaltrialsarena • Jun 04, 2024
FDA grants IND clearance for Abdera's Phase I cancer therapy trial
finance • Jun 04, 2024
[Video] Amplitude Ventures on LinkedIn: Congratulations to our portfolio company Abdera Therapeutics on the…
linkedin • Jun 04, 2024
Abdera Therapeutics Management
Leadership team at Abdera Therapeutics
Board Member
Garry Nicholson
Interim Chief Executive Officer & Co-Founder
Lana Janes
Join now and verify your accreditation status to gain access to:
- Abdera Therapeutics current valuation
- Abdera Therapeutics stock price
- Available deals in Abdera Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Abdera Therapeutics Stock
How to invest in Abdera Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Abdera Therapeutics through EquityZen funds. These investments are made available by existing Abdera Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Abdera Therapeutics stock?
Shareholders can sell their Abdera Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
